Advertisement

Investigational New Drugs

, Volume 31, Issue 5, pp 1151–1157 | Cite as

Novel bourgeonal fragrance conjugates for the detection of prostate cancer

  • Alexander SturzuEmail author
  • Sumbla Sheikh
  • Hartmut Echner
  • Thomas Nägele
  • Martin Deeg
  • Christian Schwentner
  • Marius Horger
  • Ulrike Ernemann
  • Stefan Heckl
PRECLINICAL STUDIES

Summary

The methods used for detection of prostate cancer and prostate cancer lymph node metastases in medical diagnostics leave room for improvement. Currently, no means of identifying metastasized lymph nodes other than biopsies is available. Markers which are exclusively found on prostate cancer cells present a focal point for potential imaging methods. To complement the established markers like e.g. PCA3–a noncoding mRNA sequence–and PSA–a serine protease–we investigated the ectopically expressed G-protein coupled olfactory receptor OR1D2 as a possible target for prostate-specific detection with its agonist bourgeonal which has been conjugated to two different fluorescent dyes. We performed mRNA expression analysis of the OR1D2 receptor mRNA by reverse transcriptase polymerase chain reaction on LNCaP prostate carcinoma cells and three other non-prostate derived carcinoma cell lines. Additionally, we used flow cytometry to investigate the uptake of fluorescent-dye-bound OR1D2-ligand bourgeonal into the examined carcinoma cell lines. Finally, confocal laser scanning microscopy of in vitro cell culture and in vivo tumor xenografts on mice was performed. We could confirm OR1D2 receptor mRNA overexpression as well as stronger uptake of both bourgeonal conjugates in vitro and in vivo for LNCaP cells compared to the non-prostate derived cell lines. Cytoplasmic accumulation and no adverse effects after in vitro and in vivo application of the conjugates were observed. The conjugates represent a platform for the development of future prostate-specific imaging applications, e.g. detection of metastasized lymph nodes during surgery by intraoperative laser examination.

Keywords

Prostate cancer Olfactory receptor Bourgeonal 

Notes

Acknowledgment

This study is supported by the Wilhelm Sander Foundation, the Hertie Foundation for Brain Research and the Interdisciplinary Center for Clinical Research, University of Tübingen.

Conflict of interest declaration

The authors declare that they have no conflict of interest.

References

  1. 1.
    Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161, Erratum in: (1991) N Engl J Med 325:1324CrossRefGoogle Scholar
  2. 2.
    Djavan B, Eckersberger E, Finkelstein J, Sadri H, Taneja SS, Lepor H (2010) Prostate-specific antigen testing and prostate cancer screening. Prim Care 37:441–459, viiCrossRefGoogle Scholar
  3. 3.
    Vosshall LB (2004) Olfaction: attracting both sperm and the nose. Curr Biol 14:R918–R920CrossRefGoogle Scholar
  4. 4.
    Spehr M, Schwane K, Heilmann S, Gisselmann G, Hummel T, Hatt H (2004) Dual capacity of a human olfactory receptor. Curr Biol 14:R832–R833CrossRefGoogle Scholar
  5. 5.
    Spehr M, Hatt H (2005) A potential role of odorant receptor agonists and antagonists in the treatment of infertility and contraception. Curr Opin Investig Drugs 6:364–368PubMedGoogle Scholar
  6. 6.
    Sturzu A, Echner H, Heckl S (2009) The lily-of-the-valley fragrance receptor–potential in prostate cancer imaging. Prostate 69:1599–1602CrossRefGoogle Scholar
  7. 7.
    Cook BL, Steuerwald D, Kaiser L, Graveland-Bikker J, Vanberghem M, Berke AP, Herlihy K, Pick H, Vogel H, Zhang S (2009) Large-scale production and study of a synthetic G protein-coupled receptor: human olfactory receptor 17-4. Proc Natl Acad Sci U S A 106:11925–11930CrossRefGoogle Scholar
  8. 8.
    Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627CrossRefGoogle Scholar
  9. 9.
    Angelotti T, Daunt D, Shcherbakova OG, Kobilka B, Hurt CM (2010) Regulation of G-protein coupled receptor traffic by an evolutionary conserved hydrophobic signal. Traffic 11:560–578CrossRefGoogle Scholar
  10. 10.
    Benchaib A, Delorme R, Pluvinage M, Bryon PA, Souchier C (1996) Evaluation of five green fluorescence-emitting streptavidin-conjugated fluorochromes for use in immunofluorescence microscopy. Histochem Cell Biol 106:253–256CrossRefGoogle Scholar
  11. 11.
    Henry JB, Nakamura RM, Tucker ES, Carlson IH (1991) Immunoassays in the clinical laboratory. In: Henry JB (ed) Clinical diagnosis and management by laboratory methods. WB Saunders, Philadelphia, pp 870–871Google Scholar
  12. 12.
    Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A (2010) The prostate cancer gene 3 assay: indications for use in clinical practice. BJU Int 105(4):452–455CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Alexander Sturzu
    • 1
    • 2
    Email author
  • Sumbla Sheikh
    • 2
  • Hartmut Echner
    • 2
  • Thomas Nägele
    • 1
  • Martin Deeg
    • 3
  • Christian Schwentner
    • 4
  • Marius Horger
    • 5
  • Ulrike Ernemann
    • 1
  • Stefan Heckl
    • 1
  1. 1.Department of NeuroradiologyUniversity of TübingenTübingenGermany
  2. 2.Peptide Synthesis Laboratory, Interfaculty Institute of BiochemistryUniversity of TübingenTübingenGermany
  3. 3.Mass Spectrometry Laboratory, Medicinal Research CentreUniversity of TübingenTübingenGermany
  4. 4.Department of UrologyUniversity of TübingenTübingenGermany
  5. 5.Department of RadiologyUniversity of TübingenTübingenGermany

Personalised recommendations